Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ERXL201
- Development stage
- Preclinical
- Lead developer
- EnduRx Pharmaceuticals
- Modality
- Peptides, Nanoparticles → Drug Delivery Systems
01
Overview
ERXL201 is a preclinical-stage peptide-directed polymeric nanoparticle being developed by EnduRx Pharmaceuticals for the treatment of atherosclerotic plaque. The drug is designed to target the macrophage component within atherosclerotic plaques to enable targeted delivery of therapeutic agents. This approach represents a non-lipid treatment strategy for atherosclerosis, aiming to reduce plaque burden and inflammation by specifically addressing the cellular drivers of the disease. It is currently in the preclinical development phase.
Beyond the preview
Go deeper on ERXL201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ERXL201.